Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B211 vs Herceptin in HER2-positive MBC
NCT04385563Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab-qyyp in HER2-positive metastatic breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
trastuzumab-qyyp
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT04385563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385563.